Renal Cell Carcinoma
Perspectives
Diagnosed too late
We take a course in giving bad news, but every doctor has his or her own approach.
From the Journals
Doctor urges compassionate access to specialized radiotherapy for inoperable RCC
SABR should be considered for patients with larger, inoperable kidney cancers who have no treatment options.
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
From the Journals
ICI combinations show survival benefit in advanced renal cancer
Authors of a systematic review suggest ICI combinations should be available worldwide as first-line treatment for advanced renal cancer.
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
From the Journals
Atezolizumab fails to improve outcomes in postsurgery kidney cancer
Study authors call for greater attention to patient selection for RCC adjuvant immunotherapy.
From the Journals
Is early-onset cancer an emerging global epidemic?
“This paper ... brings to light the importance of correctable lifestyle habits that may slow the rise of early onset cancers.”
Conference Coverage
Adjuvant nivo+ipilimumab fails in kidney cancer, in contrast to pembro
The results contrast with those seen with pembrolizumab in the same setting.
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.